• Celcuity flagged new disclosures on gedatolisib from its breast cancer and prostate cancer programs ahead of ESMO Congress 2026.
• Updated VIKTORIA-1 Phase 3 results will be presented in a late-breaking rapid oral session on Oct. 24, 2026.
• Data focus on additional subgroup findings in HR+/HER2- advanced breast cancer, targeting patients with PIK3CA-mutant tumors.
• Separate poster analyses will compare the gedatolisib triplet in PIK3CA wild-type disease against other post-CDK4/6 regimens.
• Another poster will present subgroup findings from a Phase 1b study of gedatolisib with darolutamide in metastatic castration-resistant prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839313) on October 05, 2026, and is solely responsible for the information contained therein.